Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era

Executive Summary

Can a company explain the situation surrounding a newly approved drug, including the effect of the indication on access, without violating off-label communication regulations?


Related Content

Off-Label Promotion Decisions Likely Made Case-by-Case, US FDA Official Says
Marathon's High-Priced Window May Not Stay Open Long
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Off-Label Communication: When Does It Align With Approved Labeling?
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts